LLY250110C820000
- 0.02
- 0.000.00%
Eli Lilly and Co Newsroom
DBS Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Cuts Target Price to $900
Argus Research Maintains Eli Lilly and Co(LLY.US) With Buy Rating
Jefferies Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Raises Target Price to $1,020
Evercore Maintains Eli Lilly and Co(LLY.US) With Hold Rating
DBS Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Announces Target Price $1,115
BofA Securities Maintains Eli Lilly and Co(LLY.US) With Buy Rating
Guggenheim Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Cuts Target Price to $973
TD Cowen has lowered the Target Price for Eli Lilly and Co to $900.
Leerink Partners Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Announces Target Price $950
TD Cowen Adjusts Price Target on Eli Lilly to $900 From $1,050, Maintains Buy Rating
Berenberg Bank Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Cuts Target Price to $970
Jefferies Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Raises Target Price to $996
Jefferies Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Raises Target Price to $996
A Quick Look at Today's Ratings for Eli Lilly and Co(LLY.US), With a Forecast Between $997 to $1,250
Jefferies Adjusts Price Target on Eli Lilly to $996 From $994
Bernstein Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Maintains Target Price $1,100
Truist Financial Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Maintains Target Price $1,029
Morgan Stanley Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Maintains Target Price $1,146
J.P. Morgan Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Maintains Target Price $1,100
Jefferies Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Maintains Target Price $994